Rotigotine transdermal system

Hospital Pharmacy

Volumn 42, Issue 10, 2007, Pages 939-947

  Cada, Dennis J ^a   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CABERGOLINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

APPLICATION SITE REACTION; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DAILY LIFE ACTIVITY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STORAGE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT CONTRAINDICATION; VOMITING; WEIGHT GAIN;

EID: 35648939908     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4210-939     Document Type: Review

References (30)

1. Neupro [package insert]. Mequon, WI: Schwarz Pharma, LLC; 2007.
2. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord. 2004;19:1432-1438.
3. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60:1721-1728.
4. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol. 2001;24:163-169.
5. Nugroho AK, Li G, Grossklaus A, Danhof M, Bouwstra JA. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. J Control Release. 2004;96:159-167.
6. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262-1267.
7. Nugroho AK, Li GL, Danhof M, Bouwstra JA. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. Pharm Res. 2004;21:844-850.
8. Babic T, Boothman B, Polivka J, et al. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin Neuropharmacol. 2006;29:238-242.
9. Cawello W, Braun M, Horstmann R, Funaki T, Tadayasu Y. Pharmacokinetics, safety and tolerability of rotigotine after transdermal patch administration in Japanese and Caucasian healthy subjects [abstract]. Mov Disord. 2006;21(suppl 15):S547.
10. Elshoff JP, Cawello W, Braun M, Horstmann R. Stable rotigotine plasma concentrations over 24 hours in patients with early-stage Parkinsons disease after once-daily transdermal administration of rotigotine [abstract]. Neurology. 2006;66(suppl 2):A293.
11. Cawello W, Elshoff JP, Boekens H, Braun M, Horstmann R. Characteristics of rotigotine elimination after patch removal [abstract]. Eur J Neurol. 2006;13(suppl 2):85.
12. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract]. J Clin Pharmacol. 2005;45:1091.
13. Watts RL, Wendt J, Nausieda PL, Boroojerdi B, Poole KH. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial [abstract]. Mov Disord. 2004;19(suppl 9):S258.
14. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272-276.
15. Poewe W, Rascol O, Giladi N, LeWitt PA, Watts RL. Long-term experience with rotigotine transdermal patch [abstract]. Eur J Neurol. 2006;13(suppl 2):322.
16. Guldenpfennig WM, Boroojerdi B, Poole KH, Sommerville KW. A dose escalation trial of rotigotine CDS in patients with early-stage idiopathic Parkinson's disease [abstract]. Mov Disord. 2004;19(suppl 9):S181.
17. Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol. 2005;28:106-110.
18. Patton J, Neilson S, Boroojerdi B. Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease [abstract]. Eur J Neurol. 2006;13(suppl 2):217.
19. LeWitt PA, Poewe W, Rascol O, Giladi N, Patton J. Overnight switch from ropinirole, pramipexole, and cabergoline to rotigotine transdermal patch [abstract]. Eur J Neurol. 2006;13(suppl 2):321.
20. Giladi N, Mair KJ, Badenhorst F, Dank N, Boroojerdi B. Effects of rotigotine transdermal patch on early morning motor function, sleep quality, and day-time sleepiness in patients with idiopathic Parkinson's disease. Results of a multicenter, multinational trial [abstract]. Eur J Neurol. 2006;13(suppl 2):74.
21. Poewe W, Rascol O, Quinn N, et al. Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease (CLEOPATRA-PD) [abstract]. Neurology. 2007;68(suppl 1):A260.
22. Poewe W, Giladi N, Maguire D, Boroojerdi B. Rotigotine transdermal patch in patients with Parkinson's disease and motor fluctuations. 24H symptom control in a placebo- and pramipexole-controlled, randomized, double-blind, double-dummy trial [abstract]. Eur J Neurol. 2006;13(suppl 2):74.
23. Stiasny-Kolster K, Garcia-Borreguero D, Saletu B, Schollmayer E, Oertel HW. Rotigotine transdermal patch improves quality of life in restless leg syndrome [abstract]. Ann Neurol. 2006;60(suppl 3):S77.
24. Trenkwalder C, Garcia-Borreguero D, Poewe W, Schollmayer E, Oertel W. Improvements over 24 months in patients with moderate to severe idiopathic restless legs syndrome treated with a rotigotine transdermal patch results from a multi-national, multi-centre, open-label, follow-up trial [abstract]. Neurology. 2007;68(suppl 1): A255.
25. Geisler P, Trenkwalder C, Schollmayer E, Oertel WH. Rotigotine transdermal patch improves daytime symptoms and activities of daily living in restless legs syndrome patients [abstract]. Mov Disord. 2006;21(suppl 15):S436.
26. Stiasny-Kolster K, Garcia-Borreguero D, Poewe W, et al. Rotigotine patch efficacy and safety in the treatment of moderate to severe restless legs syndrome results from a multi-national, long-term, open-label, multi-center trial [abstract]. J Sleep Res. 2006;15(suppl 1):179.
27. Korczyn AD, Reichman H, Boroojerdi B, Hack HJ. Rotigotine transdermal system for perioperative administration. J Neural Transm. 2007;114:219-221.
28. Watts RL, Patton JM, Poewe W, Boroojerdi B. Safety and tolerability of transdermal rotigotine in early-stage Parkinson's disease [abstract]. Ann Neurol. 2006;60(suppl 3):S82.
29. Tagliati M, Watts RL, Patton JM, Poewe W, Boroojerdi B. Safety and tolerability of transdermal rotigotine in early-stage Parkinson's disease [abstract]. Mov Disord. 2006;21(suppl 15):S563.
30. Hansen K, Braun M, Horstmann R. Low drug interaction potential of rotigotine [abstract]. J Clin Pharmacol. 2005;45:1091.